Статья
Артериальная гипертензия: роль микробиоты кишечника
Длительное время в патогенезе артериальной гипертензии (АГ) рассматривались преимущественно факторы, связанные с генетикой и эпигенетикой, окружающей средой и многочисленными нарушениями различных компонентов гомеостаза (вегетативная нервная система, иммунная система, ренин-ангиотензиновая система). Роль кишечной микробиоты как самостоятельного фактора, способного как благоприятствовать, так и противодействовать развитию АГ, получила признание относительно недавно. В обзоре представлены новые данные о влиянии кишечной бактериобиоты на развитие АГ, прямой регуляции артериального давления ее метаболитами, их влиянии на эпигенетические изменения, иммунитет и ренин-ангиотензин-альдостероновую систему.
1. Wise IA, Charchar F J. Epigenetic modifications in essential hypertension. Int J Mol Sci. 2016;17(4):451. doi:10.3390/ijms17040451
2. Ahn SY, Gupta C. Genetic programming of hypertension. Front Pediatr. 2017;5:285. doi:10.3389/fped.2017.00285
3. Aroor AR, Demarco VG, Jia G, Sun Z, Nistala R, Meinin-ger GA et al. The role of tissue Renin-Angiotensin aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol. 2013;4:161. doi:10.3389/fendo.2013.00161
4. Young CN, Davisson RL. Angiotensin-II, the brain, and hypertension: an update. Hypertension. 2015;66(5):920-926.
5. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114(11):1804-1814. doi:10.1161/HYPERTENSIONAHA.115.03624
6. Harrison DG. The immune system in hypertension. Trans Am Clin Climatol Assoc. 2014;125:130-138. doi:10.1161/HYPERTENSIONAHA.115.03624
7. Zubcevic J, Richards EM, Yang T, Kim S, Sumners C, Pepine CJ et al. Impaired autonomic nervous system-microbiome circuit in hypertension. Circ Res. 2019;125(1): 104-116. doi:10.1161/CIRCRESAHA.119.313965
8. Roager HM, Licht TR, Poulsen SK, Larsen TM, Bahla MI. Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new Nordic diet. Appl Environ Microbiol. 2014;80(3):1142-1149. doi:10.1128/AEM.03549-13
9. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Car-vajal JM et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65(6): 1331-1340. doi:10.1161/HYPERTENSIONAHA.115.05315
10. Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genom. 2015;47(6): 187-197. doi:10.1152/physiolgenomics.00136.2014
11. Durgan DJ, Ganesh BP, Cope JL, Ajami NJ, Phillips SC, Petrosino JF et al. Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension. 2016;67(2):469-474. doi:10.1161/HYPERTENSIONAHA.115.06672
12. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5(1):14. doi:10.1186/s40168-016-0222-x
13. Santisteban MM, Qi Y, Zubcevic J, Kim S, Yang T, Shenoy V et al. Hypertension-linked pathophysiological alterations in the gut. Circ Res. 2017;120(2):312-323. doi:10.1161/CIRCRESAHA.116.309006
14. Wilck N, Matus MG, Kearney SM, Olesen SW, Forslund K, Bartolomaeus H et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature. 2017;551(7682):585-589. doi:10.1038/nature24628
15. Toral M, Robles-Vera I, de la Visitacion N, Romero M, Yang T, Sanchez M et al. Critical role of interaction gut microbiota — sympathetic nervous system in regulation of blood pressure. Front Physiol. 2019;10:231. doi:10.3389/fphys.2019.00231
16. Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat Rev Nephrol. 2018;14(7):442-456. doi:10.1038/s41581-018-0018-2
17. Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA. 2013;110(11):4410-4415. doi:10.1073/pnas.1215927110
18. Natarajan N, Hori D, Flavahan S, Steppan J, Flavahan NA, Berkowitz DE et al. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41. Physiol Genom. 2016;48(11):826-834. doi:10.1152/physio-lgenomics.00089.2016
19. Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation. 2017;135(10):964-977. doi:10.1161/CIRCULATIONAHA.116.024545
20. Aleixandre A, Miguel M. Dietary fiber and blood pressure control. Food Fund. 2016;7(4):1864-1871. doi:10.1039/c5fo 00950b
21. Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J et al. Effect of dietary fiber intake on blood pressure: a metaanalysis of randomized, controlled clinical trials. J Hypertens. 2005;23(3):475-481.
22. Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014;64 (4):897-903. doi:10.1161/HYPERTENSIONAHA.114.03469
23. Qi Y, Aranda JM, Rodriguez V, Raizada MK, Pepine CJ. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension—a case report. Int J Cardiol. 2015;201:157-158. doi:10.1016/j.ijcard.2015.07.078
24. Jose PA, Raj D. Gut microbiota in hypertension. Curr Opin Nephrol Hypertens. 2015;24(5):403-409. doi:10.1097/MNH.0000000000000149
25. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension. 2004;43(2):169-175.
26. Ley RE, Tumbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023.
27. Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, Schuhmacher S et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation. 2011;124(12):1370-1381. doi:10.1161/CIRCULATIONAHA.l11.034470
28. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007; 204(10):2449-2460.
29. Chan CT, Sobey CG, Lieu M, Ferens D, Kett MM, Diep Henry et al. Obligatory role for b cells in the development of angiotensin II-dependent hypertension. Hypertension. 2015;66:1023-1033.
30. Pedrinelli R, Dell’Omo G, Di Bello V, Pellegrini G, Pucci L, Del Prato S et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol. 2004;24(12):2414-2419.
31. Costello-White R, Ryff CD, Coe CL. Aging and low-grade inflammation reduce renal function in middle-aged and older adults in Japan and the USA. Age. 2015;37(4):9808. doi:10.1007/s11357-015-9808-7
32. Santisteban MM, Ahmari N, Carvajal JM, Zingler MB, Qi Y, Kim S et al. Involvement of bone marrow cells and neuroinflammation in hypertension. Circ Res. 2015;117(2):178-191. doi:10.1161/CIRCRESAHA.117.305853
33. Callen IR, Limarzi LR. Blood and bone marrow studies in renal diseases. Am J Clin Pathol. 1950;20(1):3-23.
34. Jung C, Hugot JP, Barreau F. Peyer’s patches: the immune sensors of the intestine. Int J Inflam. 2010;2010:823710. doi:10.4061/2010/823710
35. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant. 2011;26(3):938-947. doi:10.1093/ndt/gfq580
36. Lin CJ, Chen HH, Pan CF, Chuang CK, Wang TJ, Sun FJ et al. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal. 2011;25(3):191-197. doi:10.1002/jcla.20456
37. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T. Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low- and high-protein diets. Nephron. 1990;56(3):306-311.
38. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut. 1991;32(7):754-759.
39. de Almeida Duarte JB, de Aguilar-Nascimento JE, Nascimento M, Nochi RJ. Bacterial translocation in experimental uremia. Urol Res. 2004;32(4):266-270.
40. Wang F, Jiang H, Shi K, Ren Y, Zhang P, Cheng S et al. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology. 2012;17(8):733-738. doi:10.1111/j.1440-1797.2012.01647.x
41. Shi K, Wang F, Jiang H, Liu H, Wei M, Wang Z et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci. 2014;59(9):2109-2117. doi:10.1007/s10620-014-3202-7
42. Ito S, Yoshida M. Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients. Toxins. 2014;6(2):665-678. doi:10.3390/toxins6020665
43. Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS ONE. 2012;7(3):e34026. doi:10.1371/journal.pone.0034026
44. Tang WHW, Hazen SL. Microbiome, Trimethylamine N-Oxide (TMAO), and cardiometabolic disease. Transl Res. 2017;179:108-115. doi:10.1016/j.trsl.2016.07.007
45. Cho CE, Caudill MA. Trimethylamine-N-Oxide: friend, foe, or simply caught in the cross-fire? Trends Endocrinol Metab. 2017;28(2):121-130. doi:10.1016/j.tem.2016.10.005
46. Scheppach W. Effects of short chain fatty acids on gut morphology and function. Gut. 1994;35 (1Suppl): S35-38.
47. SirichTL, PlummerNS, Gardner CD, HostetterTH, MeyerTW. Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. Clin J Am Soc Nephrol. 2014;9(9): 1603-1610. doi:10.2215/CJN.00490114
48. Andrade-Oliveira V,Amano MT, Correa-Costa M, CastoldiA, Felizardo RJ, de Almeida DC et al. Gut bacteriaproducts prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol. 2015;26 (8):1877-1888. doi:10.1681/ASN.2014030288
49. Ma J, Li H. The role ofgut microbiota in atherosclerosis and hypertension. Front Pharmacol. 2018;9:1082. doi:10.3389/fphar.2018.01082
50. Everard A, Cani PD. Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol. 2013;27(1):73-83. doi:10.1016/j.bpg.2013.03.007
51. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108(24):2993-2999.
52. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effectsof butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17(12):1519-1528. doi:10.3748/wjg.v17.i12.1519
53. Vieira EL, Leonel AJ, Sad AP, Beltrao NR, Costa TF, Ferreira TM. Oral administration of sodiumbutyrate attenuates inflammation and mucosal lesion in experimentalacute ulcerative colitis. J Nutr Biochem. 2012;23(5):430-436. doi:10.1016/j.jnutbio.2011.01.007
54. Richards EM, Pepine CJ, Raizada MK, Kim S. The gut, its microbiome, and hypertension. Curr Hypertens Rep. 2017;19 (4):36. doi:10.1007/s11906-017-0734-1